Format

Send to

Choose Destination
See comment in PubMed Commons below
Breast Cancer Res. 2000;2(4):264-7. Epub 2000 May 24.

Future possibilities in the prevention of breast cancer: luteinizing hormone-releasing hormone agonists.

Author information

  • 1USC/Norris Comprehensive Cancer Center and University of Southern California/Keck School of Medicine, Los Angeles, California 90089, USA. dspicer@hsc.usc.edu

Abstract

The cyclic production of estrogen and progesterone by the premenopausal ovary accounts for the steep rise in breast cancer risk in premenopausal women. These hormones are breast cell mitogens. By reducing exposure to these ovarian hormones, agonists of luteinizing hormone-releasing hormone (LHRH) given to suppress ovarian function may prove useful in cancer prevention. To prevent deleterious effects of hypoestrogenemia, the addition of low-dose hormone replacement to the LHRH agonist appears necessary. Pilot data with such an approach indicates it is feasible and reduces mammographic densities.

PMID:
11250719
PMCID:
PMC138786
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk